

# Prostate-specific antigen for prediction of skeletal metastases on bone scintigraphy in prostate cancer

Dear Editor,

We read with great interest the article by Manohar *et al.*<sup>[1]</sup> in the July–September 2020 edition of the journal. They conducted a retrospective analysis of medical records on 307 prostate cancer patients referred for <sup>99m</sup>Tc methylene diphosphonate (<sup>99m</sup>Tc MDP) bone scintigraphy in a nuclear medicine department in India and used receiver operator curve analysis to determine the optimal prostate-specific antigen (PSA) cutoff values for predicting skeletal metastases. The authors reported that the optimal cutoff value of serum PSA in the prediction of positive bone scan for skeletal metastases was 29.16 ng/ml, with a sensitivity and specificity of 89.0% and 74.6%, respectively. They reviewed similar studies on the subject from different settings which showed that the PSA cutoff for bone scintigraphy ranged from 10 to >30 ng/ml.<sup>[1]</sup>

In resource-limited settings where the practice of nuclear medicine remains challenging due to numerous factors including limited facilities and erratic radiopharmaceutical supply,<sup>[2]</sup> there continues to be a need to identify the predictive factors that will aid the optimal use of nuclear medicine facilities and resources as this will facilitate patient management and improve clinician satisfaction with the services provided by the nuclear medicine. Our group in 2019 published the results of a retrospective study on PSA and the risk of bone metastases in West Africans with prostate cancer in which 96 (26.5%) out of 363 study patients had skeletal metastases on <sup>99m</sup>Tc MDP bone scan.<sup>[3]</sup> In our study, a PSA cutoff value of  $\geq 20$  predicted the presence of skeletal metastases with a sensitivity and specificity of 86.5% and 41.2%, respectively. Although a cutoff value of  $\geq 30$  predicted the presence of metastases with a lower sensitivity of 72.9%, the specificity was higher at 56.2%, and 60% of cases were correctly classified. Similar to the current study by Manohar *et al.*<sup>[1]</sup> which reported an accuracy of 87%, we found that PSA had an accuracy of 72% in the prediction of skeletal metastases on bone scan.

Ritenour *et al.*<sup>[4]</sup> in their study fixed the cutoff point for serum PSA for which bone scans must be acquired at >30 ng/ml, a finding which further supports the 29.16 ng/ml cutoff

proposed by Manohar *et al.*<sup>[1]</sup> The serum PSA cutoff values in the West African population we studied were not so different from that of the Indian population.<sup>[1,5]</sup> We like Ritenour *et al.*<sup>[4]</sup> showed that Gleason score  $\geq 8$  had an increased specificity for the detection of bone metastases in prostate cancer. We were able to show in our study that both serum PSA and Gleason score were able to predict the presence of metastases with reasonable accuracy at 72% and 68%, respectively.<sup>[3]</sup>

We agree with Manohar *et al.*<sup>[1]</sup> that serum PSA is an independent predictor of bone metastases in patients with prostate cancer. Bone scintigraphy may not be useful as a routine staging investigation, especially in asymptomatic low-to-intermediate risk patients with prostate cancer in resource-limited settings.

### Financial support and sponsorship

Nil.

### Conflicts of interest

There are no conflicts of interest.

**EMMANUEL NII BOYE HAMMOND<sup>1,2</sup>,  
YAW AMPEM AMOAKO<sup>3</sup>, DENNIS ODAI LARYEA<sup>4</sup>,  
GEORGE AMOAH<sup>5</sup>**

<sup>1</sup>National Centre for Radiotherapy Oncology and Nuclear Medicine, Korle Bu Teaching Hospital, <sup>2</sup>Ghana Atomic Energy Commission, <sup>4</sup>Ghana Health Service Headquarters, Accra, <sup>3</sup>Department of Medicine, School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology, <sup>5</sup>Department of Surgery, Komfo Anokye Teaching Hospital, Kumasi, Ghana

### Address for correspondence:

Dr. Emmanuel Nii Boye Hammond,  
National Centre for Radiotherapy Oncology and Nuclear  
Medicine, Korle Bu Teaching Hospital, Accra, Ghana.  
E-mail: niiboyehammond@gmail.com

Submitted: 24-Sep-2020, Accepted: 28-Oct-2020,

Published: 26-May-2021


### REFERENCES

1. Manohar P, Rather T, Khan S. Determination of the optimal cut-off value of serum prostate-specific antigen in the prediction of skeletal metastases on technetium-99m whole-body bone scan by receiver operating characteristic curve analysis. *World J Nucl Med* 2020;19:255-9.
2. Adedapo KS, Onimode YA, Ejeh JE, Adepoju AO. Avoidable challenges

of a nuclear medicine facility in a developing nation. *Indian J Nucl Med* 2013;28:195-9.

3. Amoako YA, Hammond ENB, Assasie-Gyimah A, Laryea DO, Ankrah A, Amoah G. Prostate-specific antigen and risk of bone metastases in west Africans with prostate cancer. *World J Nucl Med* 2019;18:143-8.
4. Ritenour CW, Abbott JT, Goodman M, Alazraki N, Marshall FF, Issa MM. The utilization of Gleason grade as the primary criterion for ordering nuclear bone scan in newly diagnosed prostate cancer patients. *Sci World J* 2009;9:1040-5.
5. Kamaleshwaran KK, Mittal BR, Harisankar CN, Bhattacharya A, Singh SK, Mandal AK. Predictive value of serum prostate specific antigen in detecting bone metastasis in prostate cancer patients using bone scintigraphy. *Indian J Nucl Med* 2012;27:81-4.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Access this article online	
<p><b>Website:</b> www.wjnm.org</p>	<p><b>Quick Response Code</b></p> 
<p><b>DOI:</b> 10.4103/wjnm.wjnm_129_20</p>	

**How to cite this article:** Hammond EN, Amoako YA, Laryea DO, Amoah G. Prostate-specific antigen for prediction of skeletal metastases on bone scintigraphy in prostate cancer. *World J Nucl Med* 2021;20:327-8.

© 2021 World Journal of Nuclear Medicine | Published by Wolters Kluwer - Medknow